A patient treated with prednisone for a gout flare 1.5 weeks ago now has a recurrent flare while on a nonsteroidal anti‑inflammatory drug (NSAID), with no recent laboratory results available, and I am reluctant to prescribe another course of prednisone; how should I manage this acute gout flare?

Management of Recurrent Gout Flare After Recent Prednisone Course

Add low-dose colchicine (1.2 mg followed by 0.6 mg 1 hour later) to the current NSAID regimen for this acute recurrent flare, and immediately initiate urate-lowering therapy with low-dose allopurinol (≤100 mg/day) plus prophylaxis to prevent future flares. 1

Immediate Flare Management

Your reluctance to repeat prednisone is reasonable given the recent 1.5-week course, but this patient needs effective anti-inflammatory treatment now:

• Add colchicine to the existing NSAID rather than repeating corticosteroids. Low-dose colchicine (1.2 mg loading dose followed by 0.6 mg 1 hour later) is as effective as high-dose regimens with significantly fewer gastrointestinal adverse effects. 1

• Combination therapy is acceptable. The American College of Physicians supports using colchicine, NSAIDs, or corticosteroids—and these can be combined when monotherapy fails. 1

• If colchicine is contraindicated (renal impairment, hepatic disease, or drug interactions with CYP3A4/P-glycoprotein inhibitors), then a short course of oral corticosteroids remains appropriate despite recent use. Prednisolone 35 mg daily for 5 days has proven efficacy. 1

Critical Next Step: Initiate Urate-Lowering Therapy NOW

This recurrent flare within 1.5 weeks defines this patient as having recurrent gout (≥2 episodes), which is a strong indication for urate-lowering therapy:

• Start allopurinol during this flare rather than waiting for resolution. The 2020 ACR guidelines conditionally recommend starting ULT during an acute flare over delaying until resolution. 2

• Begin with low-dose allopurinol ≤100 mg/day (lower if any degree of CKD) and titrate upward every 2-4 weeks to achieve serum urate <6 mg/dl. Starting low reduces flare risk during initiation. 2

• Allopurinol is strongly recommended as first-line ULT over all other agents, including in patients with CKD stage ≥3. 2

Mandatory Flare Prophylaxis During ULT Initiation

• Strongly recommend concomitant anti-inflammatory prophylaxis when starting ULT. Use colchicine (0.6 mg once or twice daily), low-dose NSAIDs, or low-dose prednisone/prednisolone. 2

• Continue prophylaxis for 3-6 months minimum after ULT initiation. Shorter durations are associated with flares upon cessation—in fact, 29.7% of patients experience flares in the 3-month period immediately after stopping prophylaxis. 2, 3

• Colchicine prophylaxis is preferred over NSAIDs when possible. Recent 2025 data showed NSAIDs for prophylaxis were associated with higher cardiovascular risk (HR 1.56 for MACE) compared to colchicine among patients starting allopurinol. 4

Key Considerations and Pitfalls

Check renal function before prescribing:

• Colchicine doses must be halved in moderate renal impairment and avoided in severe renal insufficiency. 1
• NSAIDs are contraindicated in significant renal disease, heart failure, or cirrhosis. 1
• Allopurinol starting dose should be reduced further (≤50 mg/day) in CKD but can be safely titrated upward to achieve target urate levels. 2

Screen for drug interactions:

• Colchicine is contraindicated with potent CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-glycoprotein inhibitors. 1

Address the underlying problem:

• This early recurrence signals inadequate disease control. Without ULT, this patient will continue having recurrent flares. 1
• The goal is serum urate <6 mg/dl (360 µmol/L), or <5 mg/dl (300 µmol/L) in severe gout with tophi. 2

Counsel the patient:

• Explain that flares may initially increase when starting ULT (hence the prophylaxis requirement), but long-term ULT eliminates urate crystals and prevents future attacks. 2, 1
• Warn about the 3-month high-risk period after stopping prophylaxis and ensure a plan for managing breakthrough flares. 3